Morteza Mohammadzadeh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Morteza Mohammadzadeh has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Ali Amini
Department of Hematology and Blood Banking, School of Allied Medical Sciences, Iran University of Medical Sciences, Tehran, Iran
2 shared publications - Farnaz Etesam
Psychosomatic Medicine Research Center, Department of Psychiatry, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran
2 shared publications - Farzad Shidfar
Department of Nutrition, School of Public Health, Iran University of Medical Sciences, Tehran, Iran
2 shared publications - Morvarid Noormohammadi
Gastroenterology and Liver Diseases Research center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 shared publications - Pegah Khosravian
Medical Plants Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran
2 shared publications - Arash Dalvand
Environmental Science and Technology Research Center, Department of Environmental Health Engineering, School of Public Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
1 shared publication
Latest Publications
- Open Access
- 5 September 2026
- Published by Springer Nature in Scientific Reports
Functional resonance analysis method and monte carlo simulation: evaluating performance variability in a socio-technical direct reduction iron plant
- 5 September 2026
- Published by Springer Nature in Scientific Reports
Open AccessFunctional resonance analysis method and monte carlo simulation: evaluating performance variability in a socio-technical direct reduction iron plant
- 7 October 2025
- Published by Springer Nature in BioMetals
- Vol. 39 (1) , 119-131
Impact of nano-selenium supplementation add-on sertraline on depressive symptoms and oxidative stress in patients with major depressive disorder: a triple-blind randomized controlled trial
Major depressive disorder (MDD) is a prevalent psychiatric condition associated with increased oxidative stress, which may contribute to its pathophysiology. Elevated malondialdehyde (MDA) levels and reduced total antioxidant capacity (TAC) and glutathione peroxidase (GPX) activity have been observed in individuals with MDD. Nano-selenium, a novel formulation with enhanced bioavailability and antioxidant potency compared to conventional selenium, may help modulate these oxidative stress biomarkers. In this randomized, triple-blind, placebo-controlled trial, 50 adults newly diagnosed with MDD received either nano-selenium (55 µg/day) or placebo, both alongside sertraline (50 mg/day), over a 12-week period. A total of 42 participants (21 per group) completed the study. Depressive symptoms were measured using the Hamilton Depression Rating Scale (HDRS), and serum levels of GPX, TAC, and MDA were assessed at baseline and post-intervention. Compared to placebo, nano-selenium significantly reduced depressive symptoms (mean change: −5.09 ± 4.94; P < 0.001) and increased TAC (mean change: 0.03 ± 0.04 mmol/L; P = 0.003) and GPX levels (median change: 9.56 U/L; IQR: −7.86 to 30.31; P = 0.044). While MDA levels decreased significantly in both groups, between-group differences were not statistically significant. These findings suggest that nano-selenium may serve as a safe and effective adjunctive therapy for reducing depressive symptoms and improving antioxidant status in MDD. However, the short duration and modest sample size of this study limit generalizability. Larger, multicenter trials with extended follow-up are recommended to confirm and expand upon these results. This study was approved by the Research Ethics Committee of Iran University of Medical Sciences (IR.IUMS.REC.1402.206; June 13, 2023) and registered with the Iranian Registry of Clinical Trials (IRCT20091114002709N62; July 29, 2023). Written informed consent was obtained from all participants. Graphical abstract
- 7 October 2025
- Published by Springer Nature in BioMetals
- Vol. 39 (1) , 119-131
Impact of nano-selenium supplementation add-on sertraline on depressive symptoms and oxidative stress in patients with major depressive disorder: a triple-blind randomized controlled trial
Major depressive disorder (MDD) is a prevalent psychiatric condition associated with increased oxidative stress, which may contribute to its pathophysiology. Elevated malondialdehyde (MDA) levels and reduced total antioxidant capacity (TAC) and glutathione peroxidase (GPX) activity have been observed in individuals with MDD. Nano-selenium, a novel formulation with enhanced bioavailability and antioxidant potency compared to conventional selenium, may help modulate these oxidative stress biomarkers. In this randomized, triple-blind, placebo-controlled trial, 50 adults newly diagnosed with MDD received either nano-selenium (55 µg/day) or placebo, both alongside sertraline (50 mg/day), over a 12-week period. A total of 42 participants (21 per group) completed the study. Depressive symptoms were measured using the Hamilton Depression Rating Scale (HDRS), and serum levels of GPX, TAC, and MDA were assessed at baseline and post-intervention. Compared to placebo, nano-selenium significantly reduced depressive symptoms (mean change: −5.09 ± 4.94; P < 0.001) and increased TAC (mean change: 0.03 ± 0.04 mmol/L; P = 0.003) and GPX levels (median change: 9.56 U/L; IQR: −7.86 to 30.31; P = 0.044). While MDA levels decreased significantly in both groups, between-group differences were not statistically significant. These findings suggest that nano-selenium may serve as a safe and effective adjunctive therapy for reducing depressive symptoms and improving antioxidant status in MDD. However, the short duration and modest sample size of this study limit generalizability. Larger, multicenter trials with extended follow-up are recommended to confirm and expand upon these results. This study was approved by the Research Ethics Committee of Iran University of Medical Sciences (IR.IUMS.REC.1402.206; June 13, 2023) and registered with the Iranian Registry of Clinical Trials (IRCT20091114002709N62; July 29, 2023). Written informed consent was obtained from all participants. Graphical abstract
- Open Access
- 12 August 2025
- Published by Springer Nature in BMC Psychiatry
- Vol. 25 (1) , 785
Impact of Nano-Selenium supplementation on the JAK/STAT signaling pathway in major depressive disorder: a Triple-Blind, randomized controlled trial
Major depressive disorder (MDD) is a prevalent mental health condition, wherein the JAK/STAT signaling pathway serves as a potent cellular mechanism implicated in its pathophysiology. Increased expression of JAK2, STAT3, and subsequently IDO1 genes appears to be linked to depressive symptoms. With their antioxidant capabilities and improved absorption due to the nano formula, selenium nanoparticles could potentially modulate this molecular pathway. This study aimed to assess the impact of nano-selenium supplementation on the expression of JAK2, STAT3, and IDO1 genes in patients with MDD. A triple-blind, randomized, placebo-controlled trial was conducted at the Psychosomatic Clinic of Imam Khomeini Hospital Complex. A total of 50 participants, newly diagnosed with MDD were randomized to either a nano-selenium (55 µg/day) or placebo group for 12 weeks. All participants were receiving their standard treatment (sertraline 50 mg/day). Blood samples were collected at baseline and post-intervention to measure the gene expression using RT-qPCR. At the end of the study, both groups showed reductions in JAK2 and STAT3 relative gene expression after 12 weeks (P < 0.05). Although the reduction was more in the nano-selenium group, the between-group differences were not statistically significant. This study is the first to examine nano-selenium as a novel potential adjunct treatment for MDD. Though the degree of reduction in JAK2 and STAT3 levels was greater within the nano-selenium group, it appears that additional investigations are needed to elucidate its effects. The research received approval from the Research Ethics Committees of Iran University of Medical Sciences (Approval ID: IR IUMS.REC.1402.206, dated 2023-06-13) and was duly registered with the Iranian Registry of Clinical Trials (IRCT; registration number: IRCT20091114002709N62, dated 2023-07-29).
- 12 August 2025
- Published by Springer Nature in BMC Psychiatry
- Vol. 25 (1) , 785
Open AccessImpact of Nano-Selenium supplementation on the JAK/STAT signaling pathway in major depressive disorder: a Triple-Blind, randomized controlled trial
Major depressive disorder (MDD) is a prevalent mental health condition, wherein the JAK/STAT signaling pathway serves as a potent cellular mechanism implicated in its pathophysiology. Increased expression of JAK2, STAT3, and subsequently IDO1 genes appears to be linked to depressive symptoms. With their antioxidant capabilities and improved absorption due to the nano formula, selenium nanoparticles could potentially modulate this molecular pathway. This study aimed to assess the impact of nano-selenium supplementation on the expression of JAK2, STAT3, and IDO1 genes in patients with MDD. A triple-blind, randomized, placebo-controlled trial was conducted at the Psychosomatic Clinic of Imam Khomeini Hospital Complex. A total of 50 participants, newly diagnosed with MDD were randomized to either a nano-selenium (55 µg/day) or placebo group for 12 weeks. All participants were receiving their standard treatment (sertraline 50 mg/day). Blood samples were collected at baseline and post-intervention to measure the gene expression using RT-qPCR. At the end of the study, both groups showed reductions in JAK2 and STAT3 relative gene expression after 12 weeks (P < 0.05). Although the reduction was more in the nano-selenium group, the between-group differences were not statistically significant. This study is the first to examine nano-selenium as a novel potential adjunct treatment for MDD. Though the degree of reduction in JAK2 and STAT3 levels was greater within the nano-selenium group, it appears that additional investigations are needed to elucidate its effects. The research received approval from the Research Ethics Committees of Iran University of Medical Sciences (Approval ID: IR IUMS.REC.1402.206, dated 2023-06-13) and was duly registered with the Iranian Registry of Clinical Trials (IRCT; registration number: IRCT20091114002709N62, dated 2023-07-29).
- 1 October 2021
- Published by Maad Rayan Publishing Company in Environmental Health Engineering and Management
- Vol. 8 (4) , 277-286
Assessment of aflatoxin exposure using urine biomarker in pregnant and non-pregnant women in Yazd, Center of Iran
Background: Aflatoxins (AFs) are one of the most prevalent toxins, which long-term exposure to them could be a risk factor for liver cancer. AFM1 is the hydroxylated metabolite of AFB1 , therefore, the presence of AFM1 in urine samples can give an appropriate estimation of dietary AF exposure in human. Methods: The present study aimed to evaluate the excretion level of AFM1 in urine samples of pregnant and non-pregnant women in Yazd, Iran. A total of 85 urine samples (42 pregnant and 43 non-pregnant) were selected randomly from women who had referred to health centers of Yazd during March to May 2017. From each participant, a 72-hour dietary recall was asked and the data were recorded and later analyzed by ELISA kits. Results: The results showed that the mean level of AFM1 in pregnant and non-pregnant women was 8.23±2.9 and 35.5±1.05 pg mL-1, respectively. Excretion of AFM1 in urine samples had a significant relationship with some demographic factors and type of consumed foods (P<0.05). Conclusion: There was a significant relationship between the education level, place of residence, and the consumption of nuts with the excretion of AFM1 . It can be concluded that some foods distributed in Yazd are contaminated with AFs, and a significant number of people are exposed to high concentrations of AFM1 .
- 1 October 2021
- Published by Maad Rayan Publishing Company in Environmental Health Engineering and Management
- Vol. 8 (4) , 277-286
Assessment of aflatoxin exposure using urine biomarker in pregnant and non-pregnant women in Yazd, Center of Iran
Background: Aflatoxins (AFs) are one of the most prevalent toxins, which long-term exposure to them could be a risk factor for liver cancer. AFM1 is the hydroxylated metabolite of AFB1 , therefore, the presence of AFM1 in urine samples can give an appropriate estimation of dietary AF exposure in human. Methods: The present study aimed to evaluate the excretion level of AFM1 in urine samples of pregnant and non-pregnant women in Yazd, Iran. A total of 85 urine samples (42 pregnant and 43 non-pregnant) were selected randomly from women who had referred to health centers of Yazd during March to May 2017. From each participant, a 72-hour dietary recall was asked and the data were recorded and later analyzed by ELISA kits. Results: The results showed that the mean level of AFM1 in pregnant and non-pregnant women was 8.23±2.9 and 35.5±1.05 pg mL-1, respectively. Excretion of AFM1 in urine samples had a significant relationship with some demographic factors and type of consumed foods (P<0.05). Conclusion: There was a significant relationship between the education level, place of residence, and the consumption of nuts with the excretion of AFM1 . It can be concluded that some foods distributed in Yazd are contaminated with AFs, and a significant number of people are exposed to high concentrations of AFM1 .